Pegfilgrastim Biosimilars: Where Are We Now?

Document Type

Article

Publication Date

7-1-2021

Publication Title

J Adv Pract Oncol

Keywords

california; irvine; sjh

Abstract

In 1991, the U.S. Food & Drug Administration (FDA) approved rmetHuGCSF for human use. This recombinant methionyl human granulocyte colony-stimulating factor, or filgrastim, saw use in over 1 million patients in its first 5 years on the market. In 2002, the FDA approved a version of filgrastim with covalent linkage to a monomethoxypolyethylene glycol, increasing the molecular size and half-life to replace multiple days of dosing with a single injection. These medications remained standard of care for neutropenia until the Biologics Price Competition and Innovation Act of 2009 created an abbreviated pathway to licensure for biologic products. Practitioners now have their pick of numerous and expanding options for pegfilgrastim biosimilars.

Clinical Institute

Cancer

Department

Oncology

Department

Pharmacy

Link to Full Text

PSJH Full Text

Share

COinS